Breast Cancer Clinical Trials in Harbin, Heilongjiang

13 recruitingHarbin, Heilongjiang, China

Showing 113 of 13 trials

Recruiting
Not Applicable

Level I-II Axillary Irradiation in Breast Cancer With Sentinel-Node Macro-metastases

Breast CancerRadiotherapy
Fudan University1,608 enrolled15 locationsNCT07469267
Recruiting
Phase 1

A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors

Breast CancerGastric CancerOvarian Cancer+1 more
BeiGene258 enrolled24 locationsNCT06257264
Recruiting
Phase 3

Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease

Breast Cancer
Pfizer1,020 enrolled518 locationsNCT06760637
Recruiting
Phase 1

A Study of BL-M17D1 in Patients With Locally Advanced or Metastatic HER2 Positive/Negative Breast Cancer and Other Solid Tumors

Breast CancerSolid Tumor
Sichuan Baili Pharmaceutical Co., Ltd.20 enrolled2 locationsNCT06503783
Recruiting
Phase 2

A Study of YL202 in Selected Patients With Advanced Solid Tumors

Breast CancerNSCLCHNSCC+1 more
MediLink Therapeutics (Suzhou) Co., Ltd.200 enrolled82 locationsNCT06107686
Recruiting
Phase 1Phase 2

A Study of YL202 in Combination With Other Anti-tumor Therapies in Patients With Advanced Solid Tumors

Breast CancerAdvanced Solid Tumors
MediLink Therapeutics (Suzhou) Co., Ltd.414 enrolled20 locationsNCT07169994
Recruiting
Phase 3

Study to Evaluate Efficacy & Safety of Afuresertib Plus Fulvestrant in Patients With Locally Advanced or Metastatic HR+/HER2- Breast Cancer

Breast Cancer
Laekna Limited256 enrolled55 locationsNCT04851613
Recruiting
Phase 3

A Clinical Study of TQB2102 Versus Docetaxel Plus Trastuzumab and Pertuzumab in the Treatment of HER2 Positive Recurrent or Metastatic Breast Cancer

Breast Cancer
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.642 enrolled25 locationsNCT07003074
Recruiting
Phase 3

A Study to Evaluate D-0502 in Subjects With ER+ Her2- Locally Advanced or Metastatic Breast Cancer

Breast Cancer
InventisBio Co., Ltd640 enrolled2 locationsNCT06954961
Recruiting
Phase 2

The Clinical Trial of TQB2102 for Injection Against Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer

Breast Cancer
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.42 enrolled16 locationsNCT06452706
Recruiting
Phase 1

A Study of TQB2102 for Injection in Patients With Recurrent/Metastatic Breast Cancer

Breast Cancer
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.150 enrolled20 locationsNCT06115902
Recruiting
Phase 4

Albumin-bound Paclitaxel and Carboplatin Versus Epirubicin and Docetaxel for Triple-negative Breast Cancer

Breast Cancer
Shengjing Hospital110 enrolled7 locationsNCT04136782
Recruiting

Sj-subway, a Predictor for the Recurrence of High-risk Hormone Receptor-positive Breast That is Sensitive to Extended Endocrine Therapy

Breast Cancer
Shengjing Hospital1,000 enrolled12 locationsNCT04476485